Surgeries & Interventions 20221021
Abiomed’s Impella Achievements 20221021
Abiomed is celebrating a string of Impella achievements this month, including a new FDA clearance, favorable study results, and, perhaps most importantly, the final wrap-up of Impella’s post-approval studies.
Artificial Intelligence 20221019
HeartFlow Adds Plaque and RoadMap Analysis 20221019
HeartFlow announced the FDA clearance of its new Plaque and RoadMap Analysis AI solutions, making it the “first and only” company to non-invasively assess CAD using anatomy, physiology, and plaque data from coronary CTA exams.
Cardiology Pharmaceuticals 20221013
COVID Drug Paxlovid Interacts with Heart Medications 20221013
A review paper in JACC warns that the COVID antiviral Paxlovid may interact with common heart medications, potentially complicating treatment options.
Cardiology Pharmaceuticals 20221012
Merck’s $11B Acceleron Merger is Paying Off 20221012
Merck just announced that its pulmonary arterial hypertension drug candidate \delivered positive results in a pivotal Phase 3 clinical trial, potentially paving the way for a multibillion-dollar therapeutic and new hope for PAH patients.
Guidelines 20221009
Challenging the Salt Restriction Norm 20221009
A new study challenges the routine practice of restricting salt consumption in acute heart failure cases.
Cardiology Pharmaceuticals October 5, 2022
SGLT2i: A Universal Heart Failure Solution? October 5, 2022
Insights from the present study provide practical evidence to substantiate the initiation of SGLT2 inhibitors during or right after a hospitalization for heart failure.
Physician Reimbursements 20220930
Plaque AI’s Reimbursement Milestone 20220930
The small list of cardiac imaging AI solutions to earn Medicare reimbursements just got bigger, following CMS’ move to add an OPPS code for AI-based coronary plaque assessments. That represents a major milestone for Cleerly, who filed for this code and leads the plaque AI segment, and it marks another sign of progress for the business of imaging AI.
Cardiology Pharmaceuticals 20220928
Deprescribing Aspirin 20220928
For people on warfarin, discontinuing aspirin use may significantly reduce bleeding events without compromising thrombotic risks.
Surgeries & Interventions 20220923
Aggressive LDL Reduction Strategy 20220923
A new study shows aggressive in-hospital PCSK-9 therapy (plus statins) for heart attack patients would likely mean fewer deaths and cardiovascular events.
Surgeries & Interventions 20220921
Renal Denervation’s Comeback 20220921
While previous studies may have fallen short and more research might be needed, physicians and regulators can have renewed confidence that Medtronic’s Symplicity system and ReCor’s Paradise device lower blood pressure.
Preventive Cardiology 20220915
Is HFpEF an Exercise Deficiency Syndrome? 20220915
Thinking of HFpEF as an exercise deficiency syndrome will help physicians better understand the condition, recognize risk earlier, and most importantly, provide a clear path to prevention.
Cardiology Pharmaceuticals 20220914
Polypill’s Simplicity Advantage 20220914
A study in NEJM found that heart attack patients who took a “polypill” (a 3-part cocktail of aspirin, ramipril, and atorvastatin) had a lower risk of major CV events. But findings from the SECURE trial also left some docs scratching their heads.
Cardiovascular Disease Solutions 20220911
GRACE 3.0: Correcting the Default Male Risk 20220911
A Lancet-published study tackled the limitations of the GRACE 2.0 heart attack mortality risk score – namely, the systematic underestimation of mortality risk in female patients.
Surgeries & Interventions 20220902
Medtronic’s Defibrillation Innovation 20220902
A new era of implantable cardioverter-defibrillators (ICDs) may be on the horizon.
Surgeries & Interventions 20220831
PCI Fizzles in REVIVED Study 20220831
The highly anticipated REVIVED trial found that percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe ventricular dysfunction.
Guidelines 20220828
Statin Guidelines Spark Debate 20220828
The new USPSTF statin recommendations sparked debate last week, eliciting four editorials published the same day in the JAMA journal family.
Cardiovascular Disease 20220824
Obesity Paradox Bias 20220824
New findings suggest it is worse to be normal weight than to have a BMI in the obese range. Does this track? One thought leader warns of collider bias—a subtype of selection bias—within the study.
Cardiac Imaging 20220821
Echo Clues: When to Suspect Amyloidosis 20220821
Routine echocardiographic parameters may prove to be “the key” to spotting cardiac amyloidosis in the presence of aortic stenosis.
Cardiology Guidelines 20220817
Algorithm Aversion in HF Care 20220817
In this heart failure clinical trial, Yale researchers found that providing clinicians with 1-year mortality risk estimates did not improve patient outcomes nor influence decision-making.
